Skip to main content

Diadexus Stock Forecast, Price & News

0.00 (0.00 %)
(As of 12/4/2020)
Today's Range
50-Day Range N/A
52-Week Range
Volume100 shs
Average Volume5,050 shs
Market Capitalization$410.00
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DDXSQ News and Ratings via Email

Sign-up to receive the latest news and ratings for Diadexus and its competitors with MarketBeat's FREE daily newsletter.

About Diadexus

Diadexus, Inc., a diagnostics company, focuses on the development and commercialization of cardiovascular diagnostic products addressing needs in cardiovascular disease. Its products include PLAC ELISA Test and the PLAC Activity Test that are designed to provide information on traditional risk factors, such as cholesterol levels to help identify individuals at risk of suffering a heart attack or stroke. The company's PLAC ELISA Test is an aid in predicting risk for coronary heart disease (CHD) and ischemic strokes associated with atherosclerosis; and PLAC Test for Lp-PLA2 (lipoprotein-associated phospholipase A2) Activity is used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of CHD in patients with no prior history of cardiovascular events. Its pipeline of proprietary biomarkers comprises proADM, proET-1, and proANP for the treatment of heart failure. The company markets its products to various national and regional clinical reference laboratories and hospitals in the United States, Europe, and internationally. The company is based in Poway, California. On June 13, 2016, Diadexus, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the Northern District of California.


No headlines for this company have been tracked by

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Market Cap$410.00
Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.00 out of 5 stars

Medical Sector

1895th out of 2,032 stocks

Pharmaceutical Preparations Industry

743rd out of 768 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Diadexus (OTCMKTS:DDXSQ) Frequently Asked Questions

What stocks does MarketBeat like better than Diadexus?

Wall Street analysts have given Diadexus a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Diadexus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are Diadexus' key executives?

Diadexus' management team includes the following people:
  • Dr. Kenneth C. Fang, Chief Medical Officer (Age 57, Pay $390k)
  • Mr. William Harrison Hammond, VP of Sales

Who are some of Diadexus' key competitors?

What is Diadexus' stock symbol?

Diadexus trades on the OTCMKTS under the ticker symbol "DDXSQ."

How do I buy shares of Diadexus?

Shares of DDXSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Diadexus' stock price today?

One share of DDXSQ stock can currently be purchased for approximately $0.00.

How much money does Diadexus make?

Diadexus has a market capitalization of $410.00.

How many employees does Diadexus have?

Diadexus employs 38 workers across the globe.

What is Diadexus' official website?

The official website for Diadexus is

Where are Diadexus' headquarters?

Diadexus is headquartered at 349 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Diadexus?

Diadexus' mailing address is 349 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 858-455-4768 or via email at [email protected]

This page was last updated on 5/18/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.